Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06647641 · ClinicalTrials.gov registry record
The CurePSP Genetics Program
A clinical trial of Corticobasal Degeneration and Corticobasal Syndrome, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT06647641: Recruiting study of Corticobasal Degeneration and Corticobasal Syndrome, sponsored by Massachusetts General Hospital.
NCT06647641 is a study of Corticobasal Degeneration and Corticobasal Syndrome that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 1,000 participants, below the 1,845-participant average among 7 other Corticobasal Degeneration trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06647641, a study of Corticobasal Degeneration and Corticobasal Syndrome, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families. Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.
Primary Outcome
All samples will first undergo non-CLIA approved whole genome sequencing on a research basis in collaboration with Sonja Scholz, MD, PhD at the Neurodegenerative Diseases Research Unit of the National Institutes of Health (Bethesda, MD). This sequencing method allows for the identification of not only variants known to be associated with these disorders but also potentially novel variants.
Conditions Studied
Interventions
- OTHER Whole genome sequencing will be performed at the NIH
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2030-12-31 |
What NCT06647641 shows while recruiting
NCT06647641 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,845-participant average among 7 other Corticobasal Degeneration trials with a reported enrollment target (46% lower).
The record links to 9 conditions, with Corticobasal Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Whole genome sequencing will be performed at the NIH is the first listed.
NCT06647641 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06647641 about?
NCT06647641 is a clinical study titled "The CurePSP Genetics Program". This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families. Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological condi...
What is the current status of trial NCT06647641?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-10-08. Estimated completion is 2030-12-31.
What conditions does trial NCT06647641 study?
This clinical trial studies the following conditions: Corticobasal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration (CBD), MSA - Multiple System Atrophy.
What interventions are being tested in trial NCT06647641?
The interventions under investigation include: Whole genome sequencing will be performed at the NIH (OTHER).
Who is sponsoring clinical trial NCT06647641?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06647641 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corticobasal Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gait Analysis in Neurological Disease
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
Scrambler Therapy for Corticobasal Syndrome-Associated Pain
RECRUITING · NA
-
Modifiable Variables in Parkinsonism (MVP)
RECRUITING
-
Imaging Studies in Corticobasal Syndrome
RECRUITING
-
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI